Top 50 Clinical Trial Platform in Asia

Yonalink provides an AI-powered platform that streams clinical trial data in real time from electronic health records (EHRs) to electronic data capture (EDC) systems, significantly reducing manual data entry and associated errors. This solution enhances data quality and operational efficiency for clinical trial sponsors, contract research organizations (CROs), and hospitals by automating data transfer and management processes.

QuantHealth offers an AI-driven platform that simulates patient responses to therapies, optimizing drug development. By integrating multi-modal data, the platform provides predictive insights for clinical trial design, asset valuation, and portfolio management.

MEDHINI is a generative AI-powered software platform that provides genomics-based multimodal solutions for healthcare diagnostics, focusing on areas such as antimicrobial resistance and virtual clinical trials. The platform enhances diagnostic accuracy and accessibility in pulmonology, neurology, nephrology, cardiology, and oncology, addressing the need for affordable healthcare solutions with measurable social impact.

Beaconcure offers Verify, an automated solution utilizing machine learning and natural language processing for the validation of clinical trial statistical outputs. This technology enhances data accuracy and accelerates regulatory approval processes, enabling faster market entry for new drugs and vaccines.

OncoClarity develops a cancer monitoring platform that integrates longitudinal clinical, genomic, and patient-reported outcomes data to provide personalized health insights for patients and actionable information for healthcare providers. This platform addresses the challenge of fragmented health data by enabling standardized care and informed clinical decision-making in oncology.

The startup develops a medical data analysis platform that utilizes real-world medical data to enhance clinical decision-making and support analytical research. By providing consulting services and operational tools, the platform aims to improve the quality of medical care and optimize prescription practices for healthcare providers.

Farcast Biosciences develops the Farcast Human Tumor Microdynamics Platform, which generates multimodal data to model tumor response and resistance to therapies using true-to-human biological systems. This technology enables researchers to identify effective treatment regimens and predict patient responses with greater accuracy, addressing the challenge of personalized cancer therapy.

The startup operates a digital platform that integrates artificial intelligence and big data analytics to create a structured repository of patient clinical data and longitudinal health histories. This technology enhances healthcare delivery by providing organizations with actionable insights, improving patient engagement and continuity of care across various interventions and services.

THB is a healthcare data-technology platform that utilizes big data analytics to generate real-world clinical evidence and enhance patient care through a 360-degree Care Engine. By processing over 1 billion clinical parameters, THB enables healthcare enterprises to deliver hyper-personalized treatment recommendations and improve decision-making for over 20 million patients.

KYAN Therapeutics utilizes its Optim.AI™ ex vivo analytic platform to perform functional precision medicine tests that evaluate drug response using patient-derived cancer cells. This approach addresses the limitations of standard therapies by providing personalized treatment regimens based on the unique sensitivities of each patient's cancer, thereby improving treatment efficacy.

The startup develops a remote management platform that utilizes artificial intelligence, the Internet of Things, and predictive analytics to provide real-time clinical decision support. This technology enhances patient monitoring and early-stage diagnosis of critical diseases, aiming to improve outcomes and reduce neonatal mortality rates.

The startup develops an AI-driven platform that enhances fertility treatment success rates by automating clinical decision-making processes for physicians. Its integrated communication tools facilitate secure interactions among clinics, doctors, and patients, streamlining workflows specific to fertility care.

The startup provides a health technology platform that utilizes AI-driven insights to enhance clinical performance and care coordination for healthcare providers, including Accountable Care Organizations. By automating patient outreach and quality measures, the platform aims to reduce hospitalizations and improve patient outcomes while optimizing resource management.

BluMaiden Biosciences utilizes its MAIDEN™ platform to discover microbiome-derived small molecules that target disease-related pathways, leveraging extensive clinical cohort data and computational chemistry. This approach addresses the challenge of developing therapeutics for traditionally undruggable targets, ensuring bio-relevance and safety through human evidence-guided validation.

Thakaa Med utilizes artificial intelligence to analyze patient data and optimize treatment plans, enhancing clinical decision-making in healthcare settings. The platform addresses inefficiencies in patient management and care coordination, leading to improved health outcomes and reduced operational costs for providers.

The startup operates a biotech platform that utilizes a patented exosome-based drug delivery system to target cancer stem cells, minimizing the toxic effects of chemotherapy. This approach enhances treatment efficacy for cancer patients by delivering therapies directly to affected cells, thereby reducing side effects and improving overall outcomes.

Provides a blockchain-based platform that enables secure, compliant sharing and monetization of personal health data between patients, healthcare providers, and life science companies. This system streamlines post-market research, patient engagement, and real-world evidence generation, improving cohort identification, treatment adherence, and market access for novel therapies.

Sayre Therapeutics commercializes niche pharmaceuticals, medical devices, and molecular diagnostics specifically for oncology and immunology, focusing on small molecules, recombinant proteins, and monoclonal antibodies. The company addresses the high unmet medical needs in South Asia by facilitating local clinical trials and regulatory pathways for novel treatments, ultimately improving patient outcomes in cancer care.

Qmed is a digital platform that integrates AI-powered clinical assistance with seamless medical device connectivity to enhance operational efficiency in healthcare practices. By streamlining patient flow and optimizing care delivery, Qmed addresses the challenges of fragmented healthcare processes and improves overall patient outcomes.

Oncoshot utilizes a federated AI data system to connect cancer patients, caregivers, and oncologists with clinical trials worldwide, enhancing patient access to treatment options. The platform addresses challenges in trial feasibility and enrollment, improving the likelihood of successful study outcomes for healthcare providers and pharmaceutical partners.

The startup has developed a healthcare technology platform that connects patients with eligible clinical trials, facilitating direct communication between patients and pharmaceutical companies. This platform enhances patient engagement and ensures that health information is effectively shared with medical professionals, improving trial participation and patient understanding of health outcomes.

The startup develops a medical data platform that integrates real-time healthcare data through an interoperable network, enabling efficient management of clinical practice data. This platform provides tailored statistical analysis, allowing health professionals and patients to access and utilize their health information effectively.

Lind is a precision trial matching platform that utilizes AI to analyze electronic health records and generate personalized matches with over 85,000 active clinical trials based on individual medical histories. This technology enables patients to quickly identify relevant treatment options, facilitating access to innovative therapies for conditions such as cancer and diabetes.

The startup offers a document management platform tailored for the healthcare and life sciences sectors, providing standardized modules and cloud services for clinical research and trials. This platform enables medical institutions and pharmaceutical companies to enhance the management of clinical documentation and streamline workflows, improving compliance and operational efficiency.

Edocate provides a platform for healthcare professionals to engage with realistic, gamified patient simulation cases through a white-labeled app. This technology enables the measurement of behavior change and competency levels, facilitating effective knowledge transfer and decision-making in clinical scenarios.

Panacea-ml develops a machine learning-based software system that utilizes predictive analytics to enhance patient selection and trial design for clinical studies in diseases such as ALS, diabetes, and cancer. The platform reduces trial duration and costs while increasing the likelihood of successful market approval for new treatments.

Script AI provides an automated clinical documentation platform that listens, transcribes, and generates medical notes in real-time, significantly reducing the time healthcare professionals spend on documentation. By streamlining workflows and enhancing operational efficiency, the platform enables organizations to reclaim up to five hours each week per clinician, improving patient care and satisfaction.

This startup provides an AI-powered platform that automates clinical documentation and task management for healthcare providers. It streamlines workflows and creates patient-centric timelines, reducing administrative burden on practitioners and improving efficiency in patient care.

Soteria Biotherapeutics is developing switchable bispecific T-cell engagers using its T-LITE™ platform to treat solid tumors in cancer patients. This technology enables pulsatile activation of antibody therapies, resulting in safer treatments with reduced side effects and improved dosing efficacy.

The startup develops a genotyping and sequencing platform that translates genetic data into clinical applications, enabling healthcare providers to make informed treatment decisions. This technology enhances patient care and biomedical research by improving the understanding and management of diseases.

Stuff That Works develops a statistics engine that aggregates and analyzes patient-reported data to generate personalized insights for chronic conditions. This platform enables health organizations to enhance clinical trial design and drug development by providing access to a vast knowledge base of real-world outcomes from over 2.9 million members.

Massive Bio offers an AI‑powered platform that consolidates clinical trial data, drug pipelines, and genomic test results into a searchable hub. Its machine‑learning engine matches patients’ clinical profiles and biomarkers to generate real‑time eligibility scores and treatment recommendations, delivered via a secure physician dashboard and patient mobile app.

Massive Bio is an AI-powered oncology platform that matches cancer patients with over 19,000 clinical trials worldwide by analyzing their medical history and genomic profiles. The platform facilitates access to trials for patients regardless of their location or financial situation, while providing pharmaceutical companies with a streamlined way to connect with potential participants.

Psifas is developing a platform that integrates longitudinal medical records with whole genome sequencing data to facilitate targeted medical research. This approach enables early disease detection and intervention, improving health outcomes by providing researchers with comprehensive, anonymized datasets for analysis.

NetTargets utilizes AI-enhanced systems biology and mathematical modeling to provide interpretable predictions for drug discovery, significantly reducing the risk of clinical trial failures. By simulating causal biological networks, the company helps identify effective treatment strategies and optimize patient selection, addressing the high failure rates in drug development.

The company provides an integrated biopharmaceutical platform that discovers, optimizes, and manufactures novel antibodies, antibody‑drug conjugates, and small‑molecule therapeutics for oncology, autoimmune, metabolic, and ophthalmic indications. Its services include AI‑driven antibody engineering, high‑throughput screening, GMP‑scale production, and full‑cycle regulatory and clinical development to support co‑development, licensing, or contract manufacturing partnerships.

Cogniant is an AI-assisted digital health platform that passively collects digital biomarkers from diverse patient populations to enhance the efficacy of clinical trials for neurological and psychiatric disorders. By providing real-time data for expansive phenotyping and clinical state prediction, Cogniant bridges the gap between clinical trial outcomes and real-world effectiveness.

Dr. Noah Biotech utilizes an AI-driven platform to develop drug combinations specifically targeting orphan diseases, leveraging extensive bio-pharmacological data to identify effective therapeutic options. The company addresses the high failure rates in clinical trials by enhancing drug efficacy and safety through synergistic combinations, ultimately improving treatment outcomes for patients with limited therapeutic options.

The startup has developed an AI-driven healthcare data platform that aggregates and analyzes real-time health data to provide actionable insights for researchers and healthcare entities. This platform enhances symptom monitoring and risk management, leading to improved efficiency and cost reduction in healthcare research.

ACT Genomics provides genomic profiling services that deliver actionable insights on biomarkers and genomic alterations to tailor cancer treatment plans for patients. By utilizing precision testing, the company enhances treatment selection and clinical trial matching, improving patient outcomes in oncology.

The startup develops a clinical decision support system that analyzes biosignal data from critically ill patients to diagnose and predict serious diseases. This platform enhances clinical decision-making for healthcare professionals, enabling timely and informed medical interventions.

DragOnFlow is a Protocol Excellence Execution Platform that transforms complex clinical trial protocols into interactive guides, enhancing protocol adherence and minimizing errors. By providing real-time data collection and comprehensive reporting, it ensures data integrity and patient safety while accelerating trial timelines and reducing operational costs.

Shanhu Health develops clinical application software, including electronic data capture and randomization systems, to enhance the efficiency of clinical trials and drug supply chain management. Their solutions streamline data collection and regulatory compliance, significantly reducing operational costs for research institutions.

Pre-Cure utilizes a multifunctional tumor-on-a-chip platform to enhance the precision of cancer treatment selection by simulating tumor responses in a controlled environment. This technology enables biopharma companies and healthcare providers to tailor therapies based on individual tumor characteristics, improving treatment efficacy and patient outcomes.

The startup has developed a drug screening platform that utilizes pre-clinical assets to identify repurposing opportunities for small molecule cancer drugs. This technology enables healthcare providers to match patients with effective treatment options for underexplored cancer types, enhancing therapeutic outcomes.

The startup offers a clinical trials data platform that enables keyword searches for trial designs, researchers, and results, along with clinical trend reports categorized by disease, drug, region, and institution. This platform helps companies minimize the time and costs associated with conducting clinical trials by providing high-scored contract research organization (CRO) recommendations based on digital requests for proposals.

The startup develops antibody-based therapeutics and provides clinical research services to facilitate the treatment of rare and incurable diseases. By offering non-clinical and clinical project management, along with orphan drug designation, the company enhances healthcare professionals' ability to deliver targeted therapies in oncology.

SUSMED provides prescription‑grade digital therapeutic applications for chronic conditions such as insomnia, tinnitus, and chronic kidney disease, delivered via iOS and Android. It also offers a blockchain‑based clinical trial platform that records consent, randomization, and outcomes with immutable audit trails, complemented by machine‑learning analytics and FHIR‑compatible APIs for integration with EHRs and sponsor data systems. The solutions enable pharmaceutical companies, CROs, and healthcare providers to develop, monitor, and commercialize digital therapies within a compliant, cloud‑hosted environment.

The startup has developed an AI-based drug discovery engine that analyzes patient genetic data and disease mutations to identify the most effective medication for individual conditions. By comparing molecular and clinical profiles, the platform enhances treatment precision, ultimately improving patient outcomes and quality of life.

NUMENOS utilizes AI-driven Foundation Models to enhance drug development by integrating and analyzing real-world data and clinical trial data, enabling biomarker-driven target discovery and patient stratification. This approach significantly reduces trial sizes by 50-70% and increases trial significance by an average of 10 times, addressing the inefficiencies of traditional drug development methods.